The wholesale pharmaceutical company Velexfarm has been operating within Hemofarm since January
. This is the second acquisition by the Vrsac-based pharmaceutical drug manufacturer in the past six months, following the takeover of Ivancic i Sinovi in August 2016
Intensive acquisitions in the local pharmaceutical market have become a usual occurrence globally in the past years. The reason for this is that companies are constantly trying to respond to the ever shifting pharmaceutical market, and, as Hemofarm says, they fit into the trend as well, doing everything necessary to maintain and improve the entire group's market position.
– The Velexfarm acquisition was a carefully timed, conscious business move made to the end of accomplishing Hemofarm's strategic goals, above all in the healthcare domain – the company says for our portal.
– By following world trends, we intend is to raise awareness of preventive medicine in Serbia as the best starting position for maintaining health. Hemofarm's imperative is for the market to be supplied with quality, available drugs, which is why all necessary measures have been taken so that business partners, clients and the market on the whole, especially end users, shouldn't be affected by the changes in the ownership structure. At the same time, Velexfarm, as a wholesale pharmacy, will be fully meeting its obligations towards its suppliers and customers.
According to the data from Velefarm's website, among its customers are more than 700 private pharmacies with over 1,300 unloading points, 23 state-owned pharmacy institutions with 526 unloading points, and they also cooperate with nearly 50 suppliers, one of which was Hemofarm. As stated, the cooperation with Hemofarm started in 2014 with the agreement on exclusive distribution of 16 medicaments in the amount of RSD 195 million, whereas the 2016 agreement further increased the number of exclusive products in the total amount of RSD 430 million.
Velexfarm recorded a growth of sales to EUR 26.5 million in 2015, and they had 80 employees last year. As they say in Hemofarm, they will be integrated in the Hemofarm Group, as will be the employees at Ivancic.Strengthening OCT portfolio
As was the case after the acquisition of Ivancic i Sinovi, Hemofarm says that “at the moment there no plans for new acquisitions in the Serbian market”, but they add that the company has its business and development strategy and that they are planning to strengthen their regional position as the center of Stada Group for South East Europe, in line with the precise plans of the German concern.